Vigil Neuroscience (VIGL) to Release Quarterly Earnings on Tuesday

Vigil Neuroscience (NASDAQ:VIGL) is projected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Vigil Neuroscience to post earnings of ($0.51) per share for the quarter.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, analysts expect Vigil Neuroscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vigil Neuroscience Trading Down 2.0 %

NASDAQ:VIGL opened at $1.98 on Tuesday. Vigil Neuroscience has a 12 month low of $1.49 and a 12 month high of $6.06. The firm’s 50 day moving average is $2.34 and its 200 day moving average is $2.77. The stock has a market capitalization of $80.94 million, a PE ratio of -0.96 and a beta of 1.82.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright lowered their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday. Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Wedbush cut their target price on shares of Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday. William Blair assumed coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $16.25.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.